author-photo

Aisara Chansakul

Memorial Sloan Kettering Cancer Center

8

Papers

67

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.

2021 JAMA Oncology
Show All
- Source
- Cite
- Save
Citations (7)
Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

2020 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study

2020 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

2019 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study

2019 Blood
Show All
- Source
- Cite
- Save
Citations (32)
Intestinal Microbiota Composition Is Associated with Minimal Residual Disease Negativity in Patients with Multiple Myeloma

2018 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Continuous Mobile Wearable Bio-Monitoring of Newly Diagnosed Multiple Myeloma Patients Undergoing Initial Chemotherapy

2018 Blood
Show All
- Source
- Cite
- Save
Citations (1)